Mr. Mark Maicoir reports

BAUSCH HEALTH ANNOUNCES CFO TRANSITION PLAN

Tom Vadaketh, executive vice-president, chief financial officer, Bausch Health Companies Inc., has resigned from his role to pursue another opportunity and will be leaving the company effective Oct. 13, 2023. The company thanks Mr. Vadaketh for his significant contributions and leadership during a period of transition at the company.

A formal search process to identify Mr. Vadaketh's permanent replacement has been initiated.

If a permanent replacement is not in place at the time of Mr. Vadaketh's departure, the company intends to appoint John S. Barresi, who is currently serving as the company's senior vice-president, controller and chief accounting officer, to the role of interim chief financial officer. Mr. Barresi has more than 15 years of experience as a corporate finance executive.

About Bausch Health Companies Inc.

Bausch Health Companies is a global diversified pharmaceutical company whose mission is to improve people's lives with its health care products. Bausch Health develops, manufactures and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through its controlling ownership interest in Bausch + Lomb Corp. With the company's leading durable brands, it is delivering on its commitments as it builds an innovative company dedicated to advancing global health.

We seek Safe Harbor.